PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

VOLUME 49, 1994
SUBJECT AND AUTHOR INDEX

PERGAMON

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

US Editor-in-Chief

MATTHEW J. WAYNER

Division of Life Sciences, The University of Texas at San Antonio, San Antonio, TX 78249-0662

European Editor-in-Chief

SANDRA E. FILE

Psychopharmacology Research Unit, UMDS Division of Pharmacology, Guy's Hospital
P.O. Box 3448, London SE1 9QH, UK

Editorial Advisory Board

LIISA AHTEE, Helsinki, Finland
LEMBIT ALLIKMETS, Tartu, Estonia
ROBERT L. BALSTER, Richmond, VA
GIOVANNI BIGGIO, Cagliari, Italy
MIKE BRILEY, Castres, France
ALLAN C. COLLINS, Boulder, CO
DONALD V. COSCINA, Toronto, Ontario, Canada
JACQUELINE N. CRAWLEY, Bethesda, MD
ANNETTE DOMENEY, Geneva, Switzerland
ADRIAN J. DUNN, Shreveport, LA
BURR EICHELMAN, Philadelphia, PA
WILLIAM J. FREED, Washington, DC
MANUEL FREIRE-GARABAL, Santiago De Compostela, Spain
RICHARD A. GLENNON, Richmond, VA
F. G. GRAEFF, São Paulo, Brazil
M. R. C. GREENWOOD, Davis, CA
ROLAND R. GRIFFITHS, Baltimore, MD
STEPHEN G. HOLTZMAN, Atlanta, GA
AKIRA HORITA, Seattle, WA
CHRIS E. JOHANSON, Baltimore, MD
HAROLD KALANT, Toronto, Ontario, Canada
G. JEAN KANT, Washington, DC
KATHLEEN M. KANTAK, Boston, MA
GEORGE F. KOOB, La Jolla, CA
CONAN KORNETSKY, Boston, MA
J. DAVID LEANDER, Indianapolis, IN
EMINY H. Y. LEE, Taipei, Taiwan
ALLEN S. LEVINE, Minneapolis, MN
WILLIAM J. McBRIDE, Indianapolis, IN
DONALD E. McMILLAN, Little Rock, AR
JACK H. MENDELSON, Belmont, MA
FATHY S. MESSIHA, Grand Forks, ND
ROBERT D. MYERS, Greenville, NC
JUDITH A. PRATT, Glasgow, UK
JAQUELINE SAGEN, Chicago, IL
ROSARIO SAMANIN, Milan, Italy
HERMAN H. SAMSON, Winston-Salem, NC
PAUL R. SANBERG, Tampa, FL
PHIL J. SKOLNICK, Bethesda, MD
LINDA P. SPEAR, Binghamton, NY
CLARE STANFORD, London, UK
MARIE-HÉLÈNE THIÉBOT, Paris, France
DEREK VAN DER KOOY, Toronto, Ontario, Canada
JEANNE M. WEHNER, Boulder, CO
BRUNO E. WILL, Strasbourg, France
J. C. WINTER, Buffalo, NY
ALICE M. YOUNG, Detroit, MI
IAN S. ZAGON, Hershey, PA

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

US Editorial Office:
Matthew J. Wayner
Division of Life Sciences, The University of Texas at San Antonio, 6900 North Loop 1604 West
San Antonio, TX 78249-0662
Fax: (210) 691-4510

European Editorial Office:
Sandra E. File
Psychopharmacology Research Unit, UMDS Division of Pharmacology, Guy's Hospital
P.O. Box 3448, London SE1 9QH, UK
Fax: 44-(0)71-955-4627; E-mail: S.FILE@UMDS.AC.UK

Production Editor:
Alayne A. Bakken
E-mail: A.BAKKEN@ELSEVIER.COM

Publishing, Subscription, and Advertising Offices:
Elsevier Science Inc., 660 White Plains Road, Tarrytown, NY 10591-5153, USA, E-mail Address: ESUK.USA@ELSEVIER.COM; and Elsevier Science Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, England

Published Monthly

Annual Institutional Subscription Rates (1995): North, Central and South America, US$1580.00, Rest of World £1060.00. Associated Personal Subscription Rates are available on request for those whose institutions are library subscribers. Sterling prices exclude VAT. Non-VAT registered customers in the European Community will be charged the appropriate VAT in addition to the price listed. Prices include postage and insurance and are subject to change without notice.

Pharmacology Biochemistry and Behavior is an official journal of the International Behavioral Neuroscience Society. For information about the society, please contact: Marianne Van Wagner, IBNS Central Office, Division of Life Sciences, The University of Texas at San Antonio, 6900 North Loop 1604 West, San Antonio, TX 78249-0662, USA. E-mail: EDITOFF@LONESTAR.UTSA.EDU; Fax: (210) 691-4510. Members of the International Behavioral Neuroscience Society may order personal subscriptions at a concessional rate; details of this rate are available upon request.

Pergamon

Pharmacology Biochemistry and Behavior, Vol. 49, No. 4, pp. I–IX, 1994
Copyright © 1994 Elsevier Science Ltd
Printed in the USA. All rights reserved
0091-3057/94 $6.00 + .00

SUBJECT INDEX

Abuse liability, 643
Acetylcholine, 769, 807, 1067, 1075
Acoustic startle, 877, 935
Acquisition, 935
Acrylamide, 443
Active avoidance, 33
Activity feedback, 975
Adaptation, 247
Adenosine, 271
Adenosine A_1 receptors, 271
Adenosine A_2 receptors, 271
Adrenergic, 295
Adrenocortical stress response, 961
AF64A (ethyl choline mustard aziridinium), 33
Affective-motivational, 827
Age, 371, 497
Aged rats, 1075
Aggression, 313, 483
Aggressive behavior, 13
Aging monkeys, 235
Aging, 213, 683
Agonists, 295
AHR 11797, 47
α_1-Adrenergic receptors, 897
α_2-Adrenoceptors, 79
α_2 Agonists, 579
Alcogene, 417
Alcohol, 629
Alcohol drinking, 949
Alcohol intake, 417
Alcohol preference, 7
Alcohol withdrawal, 561
Alcoholism, 949
Aldehyde adduct, 949
Alfentanil, 523
Alkylation, 621
Alpha$_2$-adrenergic antagonist, 523
Alzheimer's disease, 769
Ambulatory activity, 323
Aminophylline-induced convulsions, 609
Amnesia, 849
Amnesia models, 859
Amphetamine, 41, 133, 497, 819
Amygdala, 359, 1113
Anabolic steroids, 313
Analgesia, 303, 827, 1029
Anesthesia, 523
Anesthetic, 1061
Animal communication, 835
Animal model, 549, 683
Anorectic agent, 287
Antagonists, 295, 573
Anterior hypothalamic-preoptic area, 835
Anticholinergic, 363, 813
Anticholinesterase, 363
Anticipatory vomiting, 385
Anticonvulsant, 1113
Anticonvulsant test, 47
Antidepressants, 263, 281
Antiinflammatory, 335
Antinociception, 649, 657, 675, 929, 1093
Anxiety, 327, 359, 393, 471, 549, 755, 801, 911
Anxiogenic drugs, 171
Anxiolytic-like effect, 101
Anxiolytics, 171, 281, 741
Apomorphine, 819
Appetite, 187
Arcuate nucleus, 579
Area postrema, 489
Arterial blood pressure, 489
Associative tolerance, 1029
Atipamezole, 523
Atropine, 1, 115
Attention, 683
Autoradiography, 7
Autoshaping, 1083
Avoidance behavior, 1075

Baclofen, 561
Balb/c, 433
Baroreflex, 489
Basal ganglia, 437
Basal magnocellular nucleus, 33
Behavior, 701, 795
Behavioral despair, 891
Behavioral performance, 781
Behavioral pharmacology, 1049
Behavioral sensitization, 241, 247, 583
Behavioral thermoregulation, 747
Behavioral toxicity, 503
Behavioural activity types, 263
Benzodiazepines, 359, 477, 625, 827, 921, 1113
Benzodiazepine receptors, 253
β-Carboline, 949
β-Endorphin, 1037
β_1-Adrenoceptors, 13
β_2-Adrenoceptors, 13
Blood–brain barrier, 341
Body temperature, 531
BPBA, 561
Bradykinesia, 19
Brain and plasma concentrations, 287
Brain regions, 905
Bromocriptine, 969
Buprenorphine, 241, 1017
Buspirone, 741
Butorphanol, 649, 657, 843

C57BL/6, 1109
Ca^{2+} signal, 669
Calcium, 1093
Calcium transients, 405
Calories, 629
cAMP, 1093
Cannabinoids, 929, 1093
Capsaicin-sensitive nerves, 253
Carbachol, 835
Cardiac arrest, 129
Cat odor, 219
Catalepsy, 277
Catecholamines, 33, 599
CCK-B agonists, 133
CCK-B antagonists, 433
CCK-B receptors, 133
Central benzodiazepine binding, 47
Central benzodiazepine receptor heterogeneity, 47
Central locomotor activity (antiagoraphobic Inhibition), 711
Central injection, 463
Cerebellar grafts, 443
Cerebellum, 639, 777
Cerebrolysin, 1105
Cerebrospinal fluid, 997
CGP 35348, 561
CGS 9896, 47
Change in diameter, 891
Chicks, 73, 1011
Chickadee, 363
Chlorambucil, 621
Chlordiazepoxide, 133
Cholecystokinin, 133
Cholecystokinin (CCK) receptors, 463
Cholesterol, 257
Choline acetyltransferase, 33
Cholinergic, 1, 511
Cholinergic system development, 1043
Cholinesterase, 235
Chronic aminophylline, 609
Chronic phenobarbital, 427
Chronic tolerance, 371
Chronic treatment, 859
Circadian, 327
Circadian rhythms, 975, 997
Circumventricular organ, 489
Cl^- influx, 477
Classical conditioning, 147, 583, 1061
Clenbuterol, 13
Clonidine, 79, 579, 849
Clozapine, 115, 165, 1025
Cocaine, 107, 177, 223, 229, 247, 345, 555, 583, 711, 935, 1001, 1007
Cocaine withdrawal, 223, 883
Cognition, 683

Compensatory response, 1029
Condensation product, 949
Conditioned avoidance responses, 819
Conditioned fear stress, 911
Conditioned place preference, 241, 1001
Context, 763
Context fear conditioning, 183
Continent tolerance, 1113
Continuous stress, 905
Convulsions, 561, 1113
Core temperature, 747
Cortical activation, 235
Cortical slow waves, 235
Corticosterone, 287, 729
Cortisol, 583
Counting, 943
CPT, 271
Cross tolerance, 455, 657

D_1 receptors, 73, 165, 197, 205
D_2 receptors, 73, 165, 197, 205
D_2 receptor antagonist, 19
DA autoreceptor antagonist, 345
DAGO, 737
d-Amphetamine, 345
DBA/2, 1109
DBA/2Ibg inbred mice, 257
Defense, 541
Defensive behavior, 741
Delayed matching to position, 1067
Delayed matching to sample, 427
Delayed nonmatching to position, 1067
δ-Opioid receptor, 795, 1109
δ_1 opioid receptors, 1109
δ_2 opioid receptors, 1109
Δ^9-Tetrahydrocannabinol, 763
Delta opioid receptors, 675
Dependence, 455
Depression, 165, 353, 759
Descending pathway, 675
Desipramine, 13
Development, 353, 997
Dexamethasone, 335
Dexamethasone suppression test, 961
Dexfenfluramine, 287
Dexmedetomidine, 523
Diabetes, 669
Diazepam, 253, 393, 549, 561, 609, 755, 1113
Dietary fat content, 287
Dihydro-β-erythriodine, 1
Dipeptidyl endopeptidases, 33
Discrimination learning, 213
Distress vocalizations, 327, 1011
Dizocilpine, 489, 943, 1049
DOI, 129, 165, 229
DOM, 115
Domestic chicks, 483
Domestic fowl, 1011
Dopamine (DA), 25, 73, 85, 107, 147, 353, 567, 711, 911, 969, 985
Dopamine agonist, 901
Dopamine D_2 antagonist, 323
Dopamine receptors, 247, 567
Dopaminergic neuron, 807
Dopaminergic systems, 819
Dorsal raphe, 555
DPAT, 93
DPDPE, 675, 795
Drinking, 417
Drinking behavior, 1
Drug dependence, 1049
Drug discrimination, 223, 955
Drug interaction, 335
Drug reward, 241
Drug self-administration, 233
Drug tolerance, 1049
DSLET, 1109
DSP-4, 541
DTG, 385
DuP 996, 1067, 1075

Early protein malnutrition, 393
ECoG, 235
Ectodermal microceptor preparation, 777
EEG, 235, 781, 795
8-Hydroxy-2-(di-*n*-propylamino)tetralin, 7
Electric foot shock stress, 471
Electroconvulsive shock, 849
Electrophysiology, 555
Elevated plus-maze, 133, 171, 801, 985
Elevated T-maze, 549
Emesis, 385
Endocrine effects, 583
Enriched environment, 393
Environmentally induced oral stereotypies, 295
Estradiol, 819
Ethanol, 371, 413, 417, 789
Ethanol preference, 949
Ethanol withdrawal syndrome, 969
Ethological analysis, 541, 985
Etorphine, 773
Excitatory amino acids antagonists, 413
Excitatory synaptic transmission, 1105
Exploration, 449
Exploratory activity, 801
Extinction, 935
Extrapyramidal motor system, 437
Extrapyramidal side effects, 19

F-344 rats, 1057
Factor analysis, 171
Fawn-Hooded rat, 759
Fear conditioning, 935
Feeding, 25, 85, 143, 377, 737, 843, 853
Feeding pattern, 629
Fentanyl, 773, 1017
Fetus, 795
Fever, 747
FG 7142, 133
50-kHz calls, 835
5,7-Dihydroxytryptamine, 177
5-HT, 359
5-HT_{1A}, 1083
5-HT_{1A} agonist, 385
5-HT_2 receptors, 107, 129, 165
5-HT_2 receptor antagonist, 19
5-HT_3 antagonists, 67, 385
5-HT, 449
5-HT release, 1037
Fixed-ratio, 1049
Flavored solutions, 417
Flunitrazepam, 47
Fluoxetine, 121
Flupenthixol, 883
Food caching, 363
Food carrying, 741
Food deprivation, 197
Food intake, 187, 759, 897
Food restriction, 295
Foot shock stress, 911
Foraging, 741
Forced swim, 729
Forced swimming test, 79
Forgetting functions, 427
Forskolin, 1093
Fourier analysis, 813
Fowls, 295
Free exploration test, 433
Freely moving rat paradigm, 711
Freezing, 183
Freezing behavior, 911
Frog, 277
Frontal cortex, 599
Functional and metabolic tolerance, 371

GABA, 303, 359, 449
GABA agonists, 589
GABA antagonists, 589
$GABA_B$ receptor, 561
GABA-ergic functions, 443
GABA-transaminase, 801
Gamma-vinyl GABA, 801
Gastric emptying, 253
Gastric smooth muscle, 669
GBR 12909, 345
Generalized anxiety, 219
Genetics, 417, 531, 663
Genetic differences, 975
Genetic model, 165
Glucocorticoid receptor, 961
Glucoprivation, 853
Glutamate, 835
Glutamatergic–cholinergic interactions, 689
Glycine, 303
Glycine receptor, 707
Gnawing, 737
Growth hormone, 165
Guinea pig, 133

H-7, 669
Habenula, 555
Habituation, 449
HAD rats, 417
Haldol®, 223
Hallucinogens, 599
Haloperidol, 197, 205, 223, 309, 813, 969
Handling, 393, 449
Harman, 949
Head-shake response, 107
Head-twitch response, 229
Heart rates, 489, 629, 747
Heritability, 531
Hexamethonium, 1
HI-6, 781
High-affinity choline uptake, 689
Hippocampal slices, 1105
Hippocampus, 359, 599, 949
Histamine, 853
HLö-7, 781
Hot plate, 701, 737
Human, 573, 643, 763
Hydrocortisone, 335
Hyperalgesia, 701, 1029
Hyperphagia, 47
Hypnosis, 371
Hypothermia, 47, 371
Hypoxia, 129

Ibogaine, 711
Ibotenic acid, 33
Ibuprofen, 335
ICI118,551, 13

ICS 205-930, 67
ICSS, 901
ICSS paradigm, 345
Immediate-shock deficit, 183
Immobility time, 729
Immobilization stress, 471
In vivo electrochemistry (Voltammetry), 711
In vivo receptor binding, 165
Inbred mice, 271
Inbred strains, 975
Induced seizures, 335
Inhibitors, 235
Initial discriminability, 427
Inositol, 341
Instrumental behavior, 85
Interaction, 511
Intermediate stage, 921
Intermittent stress, 905
Intracellular calcium, 1087
Intracerebroventricular, 657, 1093
Intracerebroventricular infusion, 649
Intracerebroventricular injections, 309
Intrathecal, 303, 1093
Intrathecal administration, 929
Intravenous, 1029
Ipsapirone, 165, 549
Ischemia, 129
Isolation, 13
Isolation distress, 327
Isolation stress, 1011
IV surgery, 233

Jugular catheterization, 233

Kainic acid, 33
Kappa receptor subtypes, 929
Ketamine, 1061
Ketanserin, 129, 849
Kindling, 1113

LAD, 417
Latency, 891
Layer 5, 639
Learning, 147, 1061, 1083
Learning and memory, 807
Lesion, 511
LH, 789
Li-pilocarpine seizures, 341
Licking, 813
Light/dark choice test, 433
Limbic system, 949
Linopirdine, 1067, 1075
Lithium, 341, 975, 1087
Lobeline, 877
Locomotion in open field, 47
Locomotor activity, 41, 67, 101, 241, 271, 531, 711, 1043
Locus coeruleus, 541
Long-term potentiation, 707
Long-term treatment, 263
LSD, 115
Lurcher mutants, 777

Male sexual behavior, 303
Marijuana, 187, 643, 763
Maternal deprivation, 961
Maternal induction behavior, 871
Maximal electroshock, 609
mCPP, 93, 165, 759
MDL 72222, 67
Mecamylamine, 1, 859, 877
Medial prefrontal cortex, 911
Mefenamic acid, 335
Melatonin, 327
Memory, 363, 549, 707, 849, 1061
Meperidine, 1017
Methadone, 143, 955, 1101
Methadone dependent, 1101
Methamphetamine sensitization, 323
Methlycarbamylcholine, 1
Methylenedioxyamphetamine, 599
Methylhistamine, 853
Metoprolol, 13
Metyrapone, 729
Mice, 13, 263, 323, 433
Microdialysis, 25, 107
MK-801, 489, 1049
MK-801-induced amnesia, 859
Monoamine depletion, 79
Monoamine metabolism, 471
Monoaminergic interactions, 541
Monoaminergic receptor, 961
Morphine, 649, 657, 737, 773, 1011, 1017, 1029, 1037
Morphine dependence, 1109
Morris water maze, 1075
Morris water task, 257
Motivation, 25, 85
Motor activity, 747
Motor control, 25
Motor reflex, 827
Mouse, 133, 689, 701, 871, 1043
Movement initiation, 777
μ-opioid receptors, 1109
Muscarinic receptors, 405
Muscle rigidity, 523
Muscle tone, 523
Myoclonus, 129

Naloxone, 183, 377, 573, 1011
Naloxone benzoylhydrazone, 929
Naloxone withdrawal, 1109
Naltrexone, 197, 205, 589
Naltrindole, 795
NAN-190, 385
Narcotics, 827
NECA, 271
Neonate, 1017
Neophobia, 433
Nerve agent, 503
Nerve growth factor, 701, 1043
Neurobehavioral ontogeny, 1043
Neurochemistry, 1075
Neuroleptics, 19, 813
Neuromodulation, 443
Neurotoxicity, 335
Nicotine, 1, 511, 531, 755, 769, 807, 877
Nicotine reinforcement, 67
Nictitating membrane response, 1061
Nitrous oxide, 573
NMDA receptor, 707
N-Methylcarbamylcholine phosphoinositide, 405
N-Methyl-D-aspartate, 489
N-methyl-D-aspartate receptor, 859
Nociception, 303, 737827
Nootropics, 263
Nor-binaltorphimine, 929
Noradrenaline, 13, 303, 541
Noradrenaline turnover, 905
Noradrenergic, 511
Norepinephrine, 57
NSAID, 335
Nucleus accumbens (NAcc), 85, 155, 711
Nucleus tractus solitarius, 489

Offense, 541
1-Amino-5-bromouracil (ABU), 471
1-Methyl-β-carboline, 949
One trial, 183
Open field, 801, 263
Open-field test, 961
Operant, 25, 143, 843
Operant behavior, 943
Operant feeding, 463
Operant reinforcement, 377
Opiates, 143, 303, 377, 523, 573, 579, 843
Opioid analgesia, 183, 773
Opioid mixed agonist-antagonist, 241
Opioid receptors, 773
Opioids, 197, 205, 327, 573, 625, 795, 1011
Organ weights, 905
Organophosphate, 747
Organophosphate cholinesterase, 503
Osmotic minipump, 649, 657, 949
Ovariectomy, 819
Oxazepam, 871
Oxytocin, 101

p-Chlorophenylalanine (PCPA), 483
P Rats, 417
Paeoniflorin, 213
Pain, 303, 701, 1011
Pain control system (descending), tolerance, 1037
Palatability, 417
Paradoxical sleep, 921
Paragigantocellularis, 121
Parkinson-like, 813
Parkinson's disease, 147
Parkinsonism, 437
Paroxetine, 281
Parus atricapillus, 363
Passive avoidance, 33, 849
Passive avoidance task, 807
Passive avoidance test, 859
Pavlovian facilitator, 955
PD135158, 433
Pentobarbital, 589
Peptides, 1105
Percentile schedules, 943
Performance, 497, 827
Perioral movements, 437
Pertussis toxin, 773
PGO waves, 93
Phaclofen, 561
Pharmacodynamics, 335
Phencyclidine, 1025
Photo-phobic test, 541
Physical activities, 629
Physostigmine, 363, 1067
Picrotoxin, 589
Pigeons, 385, 955
Pigs, 463
Piracetam, 683
Place approach, 1001
Plasma corticosterone, 905
Platelets, 1087
Plus-maze test, 47
Polydipsia, 1
Postintoxication incapacitation, 781
Posttreatment, 323
Potency, 643
PRE-084, 859
Preference, 417

Pregnancy, 795
Pregnant, 1101
Prenatal pup treatment, 871
Proactive interference, 427
Prolactin, 583, 789
Prolyl endopeptidase, 33
Propranolol, 13
Protective drugs, 503
Protein kinase C, 669
Psychological stress, 911
Psychomotor, 573
Psychostimulant behavior, 711
Pulsatile secretion, 789
Purkinje cells, 443
Pygmy goats, 897
Pyridostigmine, 503

Quail, 625
Quinpirole, 73, 155, 197, 205, 985

Rabbit, 599, 1061
Radioligand binding, 271, 625
Rapid eye movement (REM) sleep, 93, 413
Rats, 41, 115, 133, 171, 223, 281, 309, 393, 417, 497, 541, 555, 589, 663, 729, 741, 807, 813, 835, 849, 883, 921, 969, 1001, 1007, 1049, 1067, 1075, 1083, 1087, 1101, 1105, 1113
Rate of forgetting, 427
Rearing behavior, 711
Receptors, 1083
Receptor plasticity, 247
Receptor subtypes, 295
Rectal temperature, 165
Regression residuals, 531
Reinforcement, 25, 763, 843
Reinforcement density, 943
Reinforcement loss, 943
Reinforcing effects, 643
REM sleep deprivation, 79
Reserpine, 73, 229
Respiration, 1011
Response rate, 943
Retention, 1061
Rhesus macaque, 503
Risk assessment, 985
RJM, 663
RMI-81582, 165
Ro15-1788, 47
Rotarod performance, 443
Rotation, 147
Run length, 943
Running-wheel, 263

Satiety, 187
SCH-23390, 197, 205, 807, 985
SCH 39166, 567
Schedule-controlled behavior, 589, 1049
Schizophrenia, 155, 877
Scopolamine, 133, 363, 807, 813, 1043, 1067
Security of implantation, 639
Sedation, 101
Seizure, 1113
Selective breeding, 531
Self-administration, 177, 643, 763
Self-stimulation, 901
Senescence-accelerated mice (SAM), 769
Sensitization, 883, 935
Sensorimotor gating, 155, 877
Sensory–discriminative, 827
Septo-hippocampal pathway, 689
Septum, 689
Serotonergic drugs, 313
Serotonin, 57, 93, 107, 121, 129, 177, 303, 483, 599, 759, 849, 911, 1083
Serotonin (5-HT), 555, 711, 741
Serotonin receptors, 115
Serotonin-1A receptors, 7
Sexual behavior, 121
Sexual exhaustion, 121
Short-term memory, 683
σ sites, 859
Simple phobia, 219
Single-unit recording, 555
SKF-38393, 73, 197, 205, 985
Sleep, 93, 921
Sleep-like states, 277
Slow-wave sleep, 413
SM-9018, 19
Social interaction model, 281
Soda, 629
Soman, 503, 781
Spatial learning, 707
Spatial navigation/memory, 1075
Spatial reference memory, 689
Spinal analgesia, 773
Spinal cord, 303, 1037
Spinal GABA, 675
Spinocerebellar ataxia, 443
Startle, 155, 1025
State anxiety, 433
Steady state, 287
Stearate microelectrode, 711
Stereotypy, 711
Steroids, 335
Stimulus control, 115
Strains, 57
Stress, 57, 353, 449, 737
Stress intensity, 911
Stress–rest cyclicity, 905
Striatum, 147
Subcutaneous, 1029
Subcutaneous administration, 1007
Subjective, 573
Subjective effects, 643, 763
Subsensitive, 165
Substantia nigra, 147, 737
Subtypes, 133
Suckling, 1043
Sulpiride, 807, 985
Supraspinal, 1037
Supraspinal analgesia, 773
Surgical method, 233
Surgical procedure, 639
Swim test, 41
Swimming activity, 79
Synaptosomes, 1093

Tabun, 781
Tacrine, 213
Tail flick, 737
Tail pinch, 737
Tardive dyskinesia, 309, 663
Tele-methylhistamine, 997
Telemetry, 747
Testosterone propionate, 313
THC, 643
Theophylline, 335
Thermal nociception, 1011
Thermogenesis, 1057
Thermoregulation, 1011
Threshold, 827
Thrombin, 1087
Time course study, 165
Tobacco, 769
Tolerance, 287, 455, 477, 609, 649, 883, 1029, 1037
Tolerance dissipation, 1113
Tongue, 813
Tonic immobility, 625
Tonic nociception, 1017
Trait anxiety, 433
Transfected M_1 gene, 405
Treadmill running, 1057
Tremor, 561
Triazolam, 455
Tryptophan hydroxylase, 277
22-kHz calls, 835
2-Deoxy-D-glucose, 205, 853

(+)-UH232, 345
U-50,488, 657
U50,488H, 929
Ultrasonic vocalization, 835

Vacuous chewing movements, 309
Vasopressin, 897
Vigabatrin, 801
Vigilance, 497
Vocalizations, 827
Volunteer, 573

Water maze, 511
Withdrawal, 41, 253

Y-maze test, 859
YM-09151-2, 323

Zinc, 477
Zolpidem, 47, 455

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 49 1994

AUTHOR INDEX

Abood, L. G., 405
Adegboyega, P. A., 1087
Adell, A., 949
Afargan, M., 335
Agam, G., 341
Agrawal, A. K., 443
Ahlenius, S., 101
Airaksinen, E. M., 997
Akarsu, E. S., 969
Alleva, E., 701, 871
Almeida, S. S., 393
Aloe, L., 701
Alonso, S. J., 353
Alster, P., 101
Andreassen, O. A., 309
Andrews, N., 359
Anisman, H., 57
Arai, H., 769
Arce, A., 789
Asakura, W., 79
Aulakh, C. S., 615, 759
Ayres, J. J. B., 183

Backon, J., 335
Báez, M., 729
Baeza, R., 819
Baker, G. B., 177
Ball, W. A., 93
Barber, D. A., 579
Bardo, M. T., 241
Baskin, P. P., 437
Baskys, A., 1105
Bass, P. P., 1093
Baumeister, A. A., 737
Bednarczyk, J. M., 523
Belmaker, R. H., 341
Belzung, C., 433
Benavente, F., 819
Beninger, R. J., 363
Berkowitz, R. J., 25
Bersudsky, Y., 341
Beuzen, A., 433
Bevins, R. A., 183
Beyer, C., 303
Billington, C. J., 143, 377, 843
Blackburn, T. P., 281
Blatt, E. J., 1067
Blick, D. W., 503
Block, R. I., 1061
Boag, P. T., 363
Bodnar, R. J., 197, 205
Bonnafous, C., 253
Bonson, K. R., 313
Bontemps, R., 777
Borisenko, S. A., 33
Borland, J. L., 1011
Borowski, T. B., 935
Borszcz, G. S., 827
Botez, M. I., 777
Boyson, S. J., 147
Brioni, J. D., 755
Briscoe, R. J., 1001, 1007
Broderick, P. A., 711
Brown, G. C., 503
Brudzynski, S. M., 835
Buccafusco, J. J., 1
Buchanan, C. P., 483
Bueno, L., 253
Burke, K. A., 643
Buxton, A., 1067

Calamandrei, G., 1043
Callan, O. A., 1067
Carriero, D. L., 25
Carro, E., 789
Chait, L. D., 643
Chan, A. W. K., 371
Chen, P., 1061
Chen, S.-W., 47
Cheng, P. Y., 795
Chernet, E., 7
Chiu, T. H., 477
Cleary, J., 143
Coalson, D. W., 573
Coen, K. M., 67
Cohen, C., 455
Cole, J. C., 985
Corrigall, W. A., 67
Cousins, M. S., 25, 85
Criado, J. R., 413
Cruz, A. P. M., 171
Cunningham, K. A., 555
Curzon, P., 877
Czuczwar, S. J., 609

Darmani, N. A., 229
Das, S., 813
Daud, M. M., 393
Davies, M. F., 47
Davis, T., 733
De Acetis, L., 701
De Castro, J. M., 629
De Oliveira, L. M., 393
Decker, M. W., 877
DeFries, J. C., 531
Della Seta, D., 701
Derrien, M., 133
Dewey, W. L., 1017
Díaz-Véliz, G., 819
Dib, B., 639
Doi, C., 769
Dose, J. M., 73
Dringenberg, H. C., 741
Du, W., 599
Ducos, B., 133
Duffy, R. A., 567
Durazzo, T. C., 1001, 1007
Durieux, C., 133
Dussaubat, N., 819
Duttaroy, A., 733
Duvauchelle, C. L., 233

El-Hwuegi, A., 801
El-Zahaby, H. M., 1061
Ellinwood, E. H., Jr., 883
Elsohly, M. A., 187
Eng, F., 711
Engelman, K., 187
Esquifino, A. I., 789
Essman, W. D., 107

Fahey, K. A., 827
Feng, Y. Z., 649, 657
Fernandes, C., 359
File, S. E., 219, 359, 449, 625
Finkelstein, J. E., 707
Fiorella, D., 313
Fischman, M. W., 763
Fitten, L. J., 235
Florio, C., 271
Fluck, E., 449
Foltin, R. W., 763
Fong, C.-S., 147
Fontana, D. J., 1067, 1075
Fowler, S. C., 813
Frei, F., 171
Friedhoff, A. J., 663
Fu, X.-W., 835
Fujimoto, J. M., 675
Fuller, R. D., 737

Galbicka, G., 943
Gandolfo, G., 921
Gauvin, D. V., 223, 1001, 1007
Gendron, T. M., 583
Genkova-Papazova, M., 849
Gewiss, M. V., 589
Geyer, M. A., 155
Ghoneim, M. M., 1061
Gianutsos, G., 437
Gibson, T. R., 241
Gilhar, D., 335
Goldberg, S. R., 41, 589
Gómora, P., 303
Gondoh, Y., 905
González-Mariscal, G., 303
Gordon, C. J., 747
Gorelick, D. A., 583
Gottesmann, C., 921
Goulden, K. L., 223, 1001, 1007
Graeff, F. G., 171, 549
Gray, J. A., 511
Griffiths, J., 57
Grigoryan, G. A., 511
Grilly, D. M., 497
Grisel, J. E., 1029
Guan, X.-M., 7
Gümüşel, B., 891
Guo, X. Y., 583

Hafen, T., 975
Halgren, E., 235
Harper, D. N., 427
Harro, J., 801
Hartgraves, S. L., 503
Hartle, D. K., 489
Harvey, J. A., 599
Hasan, M., 443
Hasegawa, T., 807
Hashemi, T., 567
Hawkins, M. F., 737
Henderson, N. D., 531
Hendricks, S. E., 121
Hengemihle, J. M., 707
Henningfield, J. E., 583
Henriksen, S. J., 413
Herning, R. I., 583
Hill, J. L., 615, 759
Hill, W. L., 483
Hillegaart, V., 101
Ho, I. K., 649, 657
Hobbs, D. J., 197
Hodges, H., 511
Hoffer, B. J., 147
Hoffman, A., 335
Hogg, S., 219, 625
Holloway, F. A., 223, 1001, 1007
Holmes, B. B., 675
Homma, I., 669
Hong, E., 1083
Hope, H., 1101
Hoskins, B., 649, 657
Hubert, I., 683
Hudson, J. L., 147
Hughes, R. A., 1011
Humeniuk, R. E., 561
Husain, R., 443
Hussong, M. J., 129

Ido, H., 165
Ikasaki, Y., 769
Ikeda, K., 19
Ikemoto, S., 327
Il'ina, A. D., 1109
Imaizumi, M., 471
Inazu, M., 669
Ingram, D. K., 707
Inoue, T., 911
Inouye, G. T., 1075
Ishibashi, T., 19

Ishida, K., 19
Itoh, A., 807

Jaffard, R., 689
Jagers, T., 943
Jähkel, M., 263
Järvikylä, M., 853
Jaw, S. P., 129, 649
Johnson, C. P., 827
Johnson, R. G., 313
Johnson, R. M., 1075
Jørgensen, H. A., 309
Jou, M.-J., 405
Joyner, C., 883
Jung, J.-S., 1037

Kalynchuk, L. E., 1113
Karmanova, I. G., 277
Katono, Y., 807
Kautz, M. A., 943
Kayaalp, S. O., 891
Kayaalp, S. O., 969
Kelly, T. H., 763
Kennett, G. A., 281
Kido, H., 165
Kim, D. J. B., 877
Kim, Y.-H., 1037
King, G. R., 883
Kippin, T. E., 1113
Kiviranta, T., 997
Kiyatkin, E. A., 247
Kleinrok, Z., 609
Kling-Petersen, T., 345
Klodt, P. M., 1109
Knapp, C. M., 901
Koch, J. E., 197, 205
Koeppl, B., 583
Kofman, O., 341
Kokkinidis, L., 935
Kornelsen, R. A., 741
Kornetsky, C., 233, 901
Kostal, L., 295
Koyama, T., 911
Kozlachkova, E. Y., 277
Kulikov, A. V., 277
Kundu, G. C., 621
Kuribara, H., 323
Kuroda, Y., 961
Kutepova, O., 33

Lafuente, A., 789
Lalonde, R., 777
Lankford, M. F., 417
Laviola, G., 871
Lazarova-Bakarova, M., 849
Leander, J. D., 385
Lecklin, A., 853
Lenègre, A., 683
Levine, A. S., 143, 377, 843
Li, M., 477
Li, T.-K., 7
Lichtor, J. L., 573
Lightowler, S., 281
Ljung, E., 345
Loew, G. H., 47
Loh, E. A., 177
López, M., 789
Loron, P., 777
Lucki, I., 107
Lumeng, L., 7

Machida, H., 471
Maguire, P. A., 47
Maier, S. F., 1029
Maisky, A. I., 1109
Mann, G. L., 93
Männistö, P. T., 33
Marcó, J., 789
Marighetto, A., 689
Marks, M. J., 531
Marley, R. J., 589
Marmarosh, N., 405
Maruyama, Y., 769
Matsuguchi, N., 905
Matsumoto, K., 13, 79, 213
Matsumoto, R. R., 129
Mattes, R. D., 187
Maurice, T., 859
Mayr, M. T., 763
McBride, W. J., 7
McCallum, M. D., 737
McCormick, T. M., 1011
McCort-Tranchepain, I., 133
McCullough, L. D., 25
McIntyre, C. P., 1113
McLaughlin, C. R., 1017
McQuade, R. D., 567
Meguro, K., 769
Melchers, B. P. C., 781
Meneses, A., 1083
Micheau, J., 689
Mikuni, M., 961
Milinkevich, D., 683
Miller, M., 955
Miller, S., 257
Mills, A., 625
Mineau, P., 363
Misslin, R., 433
Mitchell, S. N., 511
Miyazaki, S., 471
Mizoguchi, K., 905
Mora, S., 819
Mori, H., 165
Mori, K. J., 961
Morrison, A. R., 93
Muneoka, K., 961
Murphy, D. L., 615, 759
Murphy, M. R., 503
Myers, R. D., 417, 949

Nabeshima, T., 807, 859
Nakamura, M., 19, 121
Nakamura, T., 769
Narita, M., 657
Navarro, E., 353
Nelson, E., 327
Nikulina, E. M., 985
Nitta, A., 807

Oehler, J., 263
Ogawa, T., 961
Ohno, Y., 19
Ohta, H., 13, 79, 213
Ojima, K., 13
Okada, K., 19
Okorodudu, A. O., 1087
Onaivi, E. S., 47
O'Neill, A. B., 755
O'Neill, J., 235
Ong, J., 561
Oreland, L., 801
Orozco, S., 629

Palumbo, P. A., 115
Panksepp, J., 327
Paris, J. M., 555
Parish, D. W., 859
Parker, B. K., 955
Parrott, R. F., 463
Paterson, S., 625
Pauly, J. R., 1
Perryman, K. M., 235
Persico, A. M., 41
Pert, A., 399
Petkov, V. D., 849
Petri, H. L., 707
Petruzzi, S., 871
Phelan, F. T., 711
Philippens, I. H. C. H. M., 781
Pickworth, W. B., 583
Pierce, T. L., 1101
Pineau, N., 433
Pinel, J. P. J., 1113
Pinto, E., 335
Popova, N. K., 277
Porsolt, R. D., 683
Prendergast, M. A., 121
Privat, A., 859
Prospero-García, O., 413
Pugh, G., Jr., 1093

Rabin, R. A., 313
Rady, J. J., 675
Rankin, J., 871
Reynolds, F. A., 233
Roberts, D. C. S., 177
Rodgers, R. J., 985
Rodriguez, M., 353
Roliński, Z., 609
Romaniuk, A., 541
Romano, A. G., 599
Roques, B. P., 133
Rosati, A. M., 271
Rosenberg, H. C., 477
Rosengarten, H., 663
Ross, R. J., 93
Rossi, R., 897
Rothman, R. B., 399, 583
Roux, S., 683
Rowland, N. E., 287
Rowlett, J. K., 241
Rudski, J. M., 143, 377, 843

Sakai, Y., 669
Sakamoto, H., 165
Salamone, J. D., 25, 85, 437
Sanford, L. D., 93
Sanger, D. J., 455
Santucci, L. B., 393
Sasaki, H., 769
Savory, C. J., 295
Scarpace, P. J., 1057
Schaal, D. W., 143, 955
Schaefer, L. A., 205
Scharrer, E., 897
Scherschlicht, R., 921
Schindler, C. W., 41, 589
Schullek, J. R., 621
Schumacher, H.-E., 263
Schweitzer, J. W., 663
Seggos, A. E., 93
Seth, P. K., 443
Shah, S., 733
Shamoto, A., 669
Shanks, N., 57
Shapiro, Y., 341
Sharma, V., 405
Shaw, L. M., 187
Sherif, F., 801
Sheu, S.-S., 405
Shiba, K., 165
Shimizu, M., 213
Shimizu, T., 905
Shrier, E. M., 483
Simon, B. B., 497
Sinden, J. D., 511
Singh, A., 107
Smolen, A., 531
Song, D.-K., 1037
Soong, Y., 795
Su, T.-P., 859
Sufka, K. J., 1011
Suh, H.-W., 1037
Sumiyoshi, T., 165
Sunal, R., 891
Suzuki, K., 165
Svensson, K., 345
Swerdlow, N. R., 155
Szeto, H. H., 795

Tackett, R. L., 579
Takahashi, K., 961
Tanaka, M., 905
Taylor, L. A., 567
Thapar, P., 573
Thompson, T., 143
Thomson, L. E., III, 583
Thorndike, E. B., 589
Tian, B., 489
Tice, M. A. B., 567
Tolliver, T., 615
Tomaz, C., 549
Traversa, U., 271
Truong, D. D., 129
Tsai, N. F., 47
Tseng, Y. T., 649, 657
Tsuchiya, K., 911
Tsuda, A., 905
Tuimisto, L., 853
Tulloch, I. F., 281
Tümer, M., 1057
Tuomainen, P., 33
Tuomisto, L., 997

Uhl, D. R., 41
Urasaki, K., 165
Uvnäs-Moberg, K., 101
Uzbay, I. T., 969

Valanzano, A., 1043
Vanderwolf, C. H., 741
Vertua, R., 271
Viana, M. B., 549
Vickers, G., 177
Volosin, M., 729
Voronina, T., 33
Voronova, I. P., 277

Wan, F. J., 155
Wang, D. X., 405
Watanabe, H., 13, 79, 213
Watkins, L. R., 1029
Watson, J. E., 427

Wechsler, R. T., 711
Wehner, J. M., 257
Weinger, M. B., 523
Welch, S. P., 929, 1093
Wessinger, W. D., 1049
White, J. M., 561
White, K. G., 427
Wieczorek, M., 541
Wiertelak, E. P., 1029
Wiley, J. L., 1025
Williamson, I. J. R., 281
Wilson, I. B., 621
Winter, J. C., 115, 313
Wlaź, P., 609
Wojtowicz, J. M., 1105
Wolff, M. C., 385
Wollnik, F., 975
Wolthuis, O. L., 781
Wong, E. H. F., 1067
Wozniak, K. M., 615
Wu, D.-L., 795

Yajnik, S., 573
Yamada, M., 769
Yamaguchi, N., 165
Yamaguchi, S., 769
Yang, X., 1
Yells, D. P., 121
Yenice, S., 1057
Yoburn, B. C., 733
Yokoo, H., 905
York, J. L., 371
Yukhananov, R. Y., 1109

Zacny, J. P., 573
Zagrodzka, J., 541
Zaitsev, S. V., 1109
Zhu, B., 669
Zolman, J. F., 73
Zolotov, N., 33